Gioacchino Catania

Adding low‐dose gemtuzumab ozogamicin to fludarabine, Ara‐C and idarubicin (MY‐FLAI) may improve disease‐free and overall survival in elderly patients with non‐M3 acute myeloid leukaemia: results of a prospective, pilot, multi‐centre trial and comparison with a historical cohort of patients

Marino Clavio, L Vignolo, Alessandra Albarello et al. · British Journal of Haematology · 2007 · 42 citations

Medicine, Hematology, Pharmacology +15

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Alessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci et al. · The Lancet Oncology · 2024 · 33 citations

Medicine, Hematology, Oncology +14

Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia

Angelo Michele Carella, Anna Garuti, Gabriella Cirmena et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 22 citations

Medicine, Genetics, Hematology +12

PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)

Roberto Santi, Manuela Ceccarelli, Gioacchino Catania et al. · Thrombosis Research · 2016 · 18 citations · Full text

Medicine, Hematology, Oncology +16

Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study

Michèle Cavo, Giulia Perrone, Silvia Buttignol et al. · Blood · 2010 · 12 citations

Medicine, Hematology, Oncology +17